Nerviano Medical Sciences Srl Announces Participation in BIO-Europe 2025
Nerviano Medical Sciences Srl is excited to announce its participation in BIO-Europe 2025, one of the premier partnering conferences for the global biotechnology and pharmaceutical industry. The event, taking place in Vienna, Austria, November 3–5, 2025, brings together innovators, investors, and industry leaders from around the world to foster collaboration, share insights, and drive forward […]
NMS ADC poster and presentation – Novel Cytotoxin and Targeted Payload Platforms at Festival of Biologics
Nerviano Medical Sciences (NMS) ADC Business Unit Portfolio Head, Rosita Lupi, delivered an oral presentation at the Festival of Biologics in Basel (30/09/2025): “Reinventing Cytotoxins and Targeted Molecules as Next-Generation Payloads for ADCs.” The session was very well received, with a full room of attendees engaged in the discussion—highlighting the strong interest in our approach […]
Nerviano Medical Sciences Srl Launches China Subsidiary to Advance Oncology Pipeline and ADC Portfolio
Nerviano, Italy – Shanghai, China 1 August 2025 — Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced today the expansion of its presence in Asia with the establishment of Nerviano Medical Sciences (Shanghai) Ltd. The new subsidiary, incorporated in Shanghai, places NMS in one of the […]
Nerviano Medical Sciences Srl Announces its plan to focus its portfolio on 3 biological targets and ADC platform
NERVIANO, Italy, 23 July 2025 — Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced its strategic plan to focus its research and development resources to progress its three biological targets, composed of PARP1, PARP7, and MPS1, and on its proprietary ADC platform composed of novel ADC […]
NMS Group S.p.A. appoints Victor Chu to Board of Directors
Nerviano, Italy – 09 July 2025 – NMS Group S.p.A., the largest oncology-focused R&D organization in Italy, today announced the appointment of Mr. Victor Chu to its Board of Directors, effective immediately. Mr. Chu replaces Mr. Lincoln Pan, who has stepped down from the Board after a period of dedicated and impactful service. “We are […]
Nerviano Medical Sciences Initiates Combination Phase 1 Trials of NMS-293 in Relapsed Small Cell Lung and BRCA Wild-Type Ovarian Cancers
Nerviano Medical Sciences Initiates Combination Phase 1 Trials of NMS-293 in Relapsed Small Cell Lung and BRCA Wild-Type Ovarian Cancers NERVIANO, Italy and BOSTON, Mass., 28 April 2025 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage oncology company developing targeted therapies across DNA damage response and kinase pathways, today announced the initiation of two Phase […]
Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement
Nerviano Medical Sciences Srl Announces Rozlytrek® (Entrectinib) Royalty Agreement – NMS to receive up to $21 Million – Financing proceeds will be used to advance NMS’s proprietary PARP1-selective, non-trapping, brain-penetrant, inhibitor NMS-293, as well as its selective PARP7 inhibitor atamparib NERVIANO, Italy and NEW YORK, NY, March 31, 2025 – Nerviano Medical Sciences S.r.l. (NMS), and […]
Nerviano Medical Sciences’ presentation from the 8th Annual DDR Inhibitors Summit is now available
We’re thrilled to share the presentation delivered by Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, Guest Speaker at the recent 8th Annual DDR Inhibitors Summit. Lisa’s presentation “Exploring Next-Gen PARP Inhibitors without PARP Trapping” focused on preclinical features and preliminary clinical data of the highly unique non-trapping, PARP1 […]
Nerviano Medical Sciences is presenting at the 8th Annual DDR Inhibitors Summit
We are excited to announce that Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, will participate as a Guest Speaker at the 8th Annual DDR Inhibitors Summit taking place in Boston from January 28-30. Lisa’s presentation Exploring Next-Gen PARP Inhibitors without PARP Trapping, scheduled for January 30th at 3:45 […]
Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma
Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma NERVIANO, Italy and BOSTON, Mass.,13 January 2025 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., […]